Arthur C. Butcher - Nov 25, 2024 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP& Grp Pres, MedSurg & APAC
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Nov 25, 2024
Transactions value $
-$1,161,099
Form type
4
Date filed
11/25/2024, 05:46 PM
Previous filing
Aug 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $72.1K +3.18K +29.41% $22.71 14K Nov 25, 2024 Direct F1
transaction BSX Common Stock Options Exercise $17.4K +1.01K +7.22% $17.26 15K Nov 25, 2024 Direct F1
transaction BSX Common Stock Sale -$1.25M -14K -93.47% $89.27 978 Nov 25, 2024 Direct F1, F2
holding BSX Common Stock 13.4K Nov 25, 2024 By 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -1.01K -20% $0.00 4.04K Nov 25, 2024 Common Stock 1.01K $17.26 Direct F1, F4
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -3.18K -20% $0.00 12.7K Nov 25, 2024 Common Stock 3.18K $22.71 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 22, 2023.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $88.76 to $89.74 inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F4 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F5 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on June 1, 2017, the first anniversary of the date of grant.